We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Genomic Health's GPS Predicts Metastatic Prostate Cancer
Read MoreHide Full Article
Genomic Health, Inc. , a global cancer company, recently unveiled positive results regarding Oncotype DX Genomic Prostate Score (GPS). The new data from a large multi-center validation study, confirmed that the GPS is a strong independent predictor of metastases in prostate cancer patients across all National Comprehensive Cancer Network (NCCN) clinical risk groups.
For the past one month, Genomic Health has been trading above the Zacks categorized Medical - Biomedical and Genetics industry. The stock gained 5.9%, much higher than the industry’s loss of 2.2%. We believe that the company is currently riding high on its presentation of positive data related to its cancer scores. Very recently, Genomic Health revealed new findings from 15 Oncotype DX Breast Recurrence Score studies. We expect that the favorable dataset of Oncotype DX GPS would further maintain the bullish trend.
Coming back to the news, Metastasis is the spread of a cancer or other disease from one organ or part of the body to another without being directly connected with it. GPS generally offers low-risk patients the opportunity to avoid prostatectomy or radiation while identifying men who need immediate definitive treatment.
The recent dataset showed a range of 10-year risk within each NCCN risk group and confirmed that the GPS was strongly associated with metastases when compared to other risk criteria. It also provided additional information about tumor aggressiveness and long-term outcomes. The study further unveiled that no patient with low- or intermediate-risk prostate cancer and a GPS result of less than 20 developed metastatic disease following radical prostatectomy.
As claimed by management, the study suggests this test may further help the physicians to explain to patients with newly diagnosed prostate cancer what his risk of developing metastatic disease is. It will also help them in making better decisions on whether to pursue active surveillance or receive definitive treatment.
According to a Market Research Store report, global demand for cancer diagnostics is poised to be worth $128.6 billion in 2020, growing at a CAGR of 7.6%. Given the rising incidence of prostate cancer and expenditure involved in its treatment, Genomic Health continues its effort to optimize the disease by addressing its overtreatment.
Zacks Rank & Key Picks
Genomic Health currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical product sector are Inogen, Inc. (INGN - Free Report) , Orasure Technologies, Inc. (OSUR - Free Report) and ZELTIQ Aesthetics, Inc. . While Inogen sports a Zacks Rank #1 (Strong Buy), Orasure and ZELTIQ Aesthetics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen gained 70.5% in the last one year in comparison to the S&P 500’s gain of 14.6%. The company has a stellar four-quarter positive average earnings surprise of over 49.08%.
Orasure surged 73.9% in the last one year in comparison to the S&P 500. It has a four-quarter positive average earnings surprise of 123.5%.
ZELTIQ Aesthetics gained over 100% in the past one year, better than the S&P 500 mark. It also has a trailing positive average earnings surprise of 12.03%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Genomic Health's GPS Predicts Metastatic Prostate Cancer
Genomic Health, Inc. , a global cancer company, recently unveiled positive results regarding Oncotype DX Genomic Prostate Score (GPS). The new data from a large multi-center validation study, confirmed that the GPS is a strong independent predictor of metastases in prostate cancer patients across all National Comprehensive Cancer Network (NCCN) clinical risk groups.
For the past one month, Genomic Health has been trading above the Zacks categorized Medical - Biomedical and Genetics industry. The stock gained 5.9%, much higher than the industry’s loss of 2.2%. We believe that the company is currently riding high on its presentation of positive data related to its cancer scores. Very recently, Genomic Health revealed new findings from 15 Oncotype DX Breast Recurrence Score studies. We expect that the favorable dataset of Oncotype DX GPS would further maintain the bullish trend.
Coming back to the news, Metastasis is the spread of a cancer or other disease from one organ or part of the body to another without being directly connected with it. GPS generally offers low-risk patients the opportunity to avoid prostatectomy or radiation while identifying men who need immediate definitive treatment.
The recent dataset showed a range of 10-year risk within each NCCN risk group and confirmed that the GPS was strongly associated with metastases when compared to other risk criteria. It also provided additional information about tumor aggressiveness and long-term outcomes. The study further unveiled that no patient with low- or intermediate-risk prostate cancer and a GPS result of less than 20 developed metastatic disease following radical prostatectomy.
Genomic Health, Inc. Price
Genomic Health, Inc. Price | Genomic Health, Inc. Quote
As claimed by management, the study suggests this test may further help the physicians to explain to patients with newly diagnosed prostate cancer what his risk of developing metastatic disease is. It will also help them in making better decisions on whether to pursue active surveillance or receive definitive treatment.
According to a Market Research Store report, global demand for cancer diagnostics is poised to be worth $128.6 billion in 2020, growing at a CAGR of 7.6%. Given the rising incidence of prostate cancer and expenditure involved in its treatment, Genomic Health continues its effort to optimize the disease by addressing its overtreatment.
Zacks Rank & Key Picks
Genomic Health currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical product sector are Inogen, Inc. (INGN - Free Report) , Orasure Technologies, Inc. (OSUR - Free Report) and ZELTIQ Aesthetics, Inc. . While Inogen sports a Zacks Rank #1 (Strong Buy), Orasure and ZELTIQ Aesthetics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen gained 70.5% in the last one year in comparison to the S&P 500’s gain of 14.6%. The company has a stellar four-quarter positive average earnings surprise of over 49.08%.
Orasure surged 73.9% in the last one year in comparison to the S&P 500. It has a four-quarter positive average earnings surprise of 123.5%.
ZELTIQ Aesthetics gained over 100% in the past one year, better than the S&P 500 mark. It also has a trailing positive average earnings surprise of 12.03%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>